Literature DB >> 24525523

Implementation of EuroSCORE II as an adjunct to APACHE II model and SOFA score, for refining the prognostic accuracy in cardiac surgical patients.

G G Tsaousi1, A A Pitsis, G D Ioannidis, C K Pourzitaki, M N Yannacou-Peftoulidou, D G Vasilakos.   

Abstract

AIM: The aim of this paper was to assess the comparable applicability of European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), Acute Physiology and Chronic Health Evaluation (APACHE II) and Sequential Organ Failure (SOFA) scores, in cardiac surgical population, on the basis of morbidity and mortality.
METHODS: EuroSCORE II, APACHE II score and SOFA score derivatives such as TMS (total maximum SOFA), MaxSOFA (single-day maximum total), SOFA 1 (admission SOFA), ΔSOFA (TMS minus SOFA 1), ΔmaxSOFA (MaxSOFA minus SOFA 1) and mean SOFA (daily SOFA to ICU stay), were prospectively calculated for 1058 consecutive patients admitted to postcardiac surgery intensive care unit (ICU). The study endpoints were length of ICU stay (LOS-ICU) and hospital mortality.
RESULTS: A disproportionate elevation of the studied algorithms was associated with prolonged LOS-ICU (P<0.001). TMS, MeanSOFA, MaxSOFA and EuroSCORE II provided better discrimination for in-hospital death [area under the receiver operating characteristic curve (AUC) 0.949, 0.929, 0.927 and 0.906, respectively] and LOS-ICU more than 2 days (AUC 0.853, 0.823, 0.819 and 0.806, respectively), compared to other risk models. EuroSCORE II, TMS and MeanSOFA were also identified as independent predictors of prolonged LOS-ICU.
CONCLUSION: EuroSCORE II seems to confer noteworthy prognostic value, being almost equivalent to that of TMS, MeanSOFA and MaxSOFA scores, and superior than APACHE II in cardiac surgical population. Thus, EuroSCORE II emerges as an imperative adjunct to ICU-based APACHE II and SOFA algorithms as it enables risk stratification, morbidity and mortality prediction even from preoperative assessment.

Entities:  

Mesh:

Year:  2014        PMID: 24525523

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  6 in total

1.  The APACHE II Score as a Predictor of Mortality After Open Heart Surgery.

Authors:  Mihriban Yalçın; Eda Gödekmerdan; Kaptanıderya Tayfur; Serkan Yazman; Melih Ürkmez; Yusuf Ata
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-09-12

2.  Is Vasoactive-Inotropic Score a Predictor for Mortality and Morbidity in Patients Undergoing Coronary Artery Bypass Surgery?

Authors:  Pınar Karaca Baysal; Füsun Güzelmeriç; Ersin Kahraman; Mustafa Emre Gürcü; Atakan Erkılınç; Tülay Orki
Journal:  Braz J Cardiovasc Surg       Date:  2021-12-03

3.  Determining and Comparing Predictive and Intensity Value of Severity Scores - "Sequential Organ Failure Assessment Score," "Acute Physiology and Chronic Health Evaluation 4," and "Poisoning Severity Score" - in Short-Term Clinical Outcome of Patients with Poisoning in an ICU.

Authors:  Koroush Ebrahimi; Ali Akbar Vaisi Raigani; Rostam Jalali; Mansour Rezaei
Journal:  Indian J Crit Care Med       Date:  2018-06

4.  Severity Index Performance in Predicting Postoperative Complications of Coronary Artery Bypass Grafting.

Authors:  Alexandre de Matos Soeiro
Journal:  Arq Bras Cardiol       Date:  2020-09       Impact factor: 2.667

5.  The usefulness of plasma levels of mature and total adrenomedullin as biomarkers indicating the magnitude of surgical stress responses: A single-center, prospective, observational study.

Authors:  Go Otao; Toyoaki Maruta; Tetsu Yonaha; Koji Igarashi; Sayaka Nagata; Kazuo Kitamura; Isao Tsuneyoshi
Journal:  J Clin Transl Res       Date:  2021-05-14

6.  Reintubation of patients submitted to cardiac surgery: a retrospective analysis.

Authors:  Cíntia Yukie Shoji; Luciana Castilho de Figuereido; Eveline Maria Calixtre; Cristiane Delgado Alves Rodrigues; Antonio Luis Eiras Falcão; Pedro Paulo Martins; Ana Paula Ragonete Dos Anjos; Desanka Dragosavac
Journal:  Rev Bras Ter Intensiva       Date:  2017 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.